Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | SMO | Q99835 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 3/20 | 0.42 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.41 |
| ▸ | APOB | P04114 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499684 | 0.91 | SMO (0.50) | SMOGAAMAPTTRPV1NPC1 | |
| SCHEMBL6794869 | 0.88 | SMO (0.56) | HTR2CHTR2AHTR2BSMOL3MBTL1 | |
| SCHEMBL6487848 | 0.87 | SMO (0.46) | SMOGAAMAPTTRPV1NPC1 | |
| SCHEMBL6491596 | 0.86 | NPC1 (0.53) | SMOGAAMAPTTRPV1NPC1 | |
| SCHEMBL6497088 | 0.85 | HTR2C (0.51) | HTR2CHTR2AHTR2BSMOGAA | |
| SCHEMBL7086871 | 0.85 | HTR2C (0.49) | HTR2CHTR2AHTR2BSMOGAA | |
| SCHEMBL6788361 | 0.85 | SMO (0.56) | HTR2CHTR2AHTR2BSMOL3MBTL1 | |
| SCHEMBL6794939 | 0.82 | HTR2C (0.48) | HTR2CHTR2AHTR2BSMOMAPT | |
| SCHEMBL7080705 | 0.81 | SMO (0.49) | SMOGAATRPV1MTTPAPOB | |
| SCHEMBL6793327 | 0.80 | SMO (0.59) | SMOGAATRPV1MTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | HTR2C 1453/4885HTR2A 659/4885HTR2B 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.